Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2026-04-06 @ 9:57 PM
Study NCT ID:
NCT00220402
Status:
COMPLETED
Last Update Posted:
2008-11-24
First Post:
2005-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-07
Start Date Type:
None
Primary Completion Date:
2007-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-07
Completion Date Type:
ACTUAL
First Submit Date:
2005-08-30
First Submit QC Date:
None
Study First Post Date:
2005-09-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-11-21
Last Update Post Date:
2008-11-24
Last Update Post Date Type:
ESTIMATED